Diarrhea News and Research

Latest Diarrhea News and Research

Ampyra receives FDA approval for improving walking in MS patients

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

23 Jan 2010

New research suggests prolong breastfeeding is critical for reducing risk of gastroenteritis in infants

For African infants with HIV-positive mothers, reducing exposure to breast milk can lower the rate of HIV transmission. But new research suggests that longer periods of breastfeeding—at least 6 months—are critical for reducing the risk of potentially fatal gastroenteritis.

21 Jan 2010

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today that Afinitor(R) (everolimus), a once-daily oral cancer treatment, has been approved by Health Canada for patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer, after failure of initial treatment with VEGF-receptor targeted therapies Sutent(R) (sunitinib) or Nexavar(R) (sorafenib).

20 Jan 2010

Urgent aid shipment containing tents and family survival kits docked at Jacmel, Haiti

An urgent aid shipment containing 4,000 tents and more than 300 family survival kits has just docked at the Haitian coastal town of Jacmel.

19 Jan 2010

Humanitarian group's response targets vulnerable women and children in Haiti

CARE warned Saturday that pregnant women, breastfeeding mothers and young children are at greatest risk in the wake of an earthquake that has devastated the Haitian capital of Port-au-Prince and left nearly three million people in need of assistance.

19 Jan 2010

Over-the-counter medications can help manage minor ailments

Nonprescription medications in the home medicine cabinet could save a trip to the doctor. The January issue of Mayo Clinic Health Letter lists more than a dozen over-the-counter medications that can help manage minor ailments.

18 Jan 2010

FDA extends Tarceva's sNDA review period

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.

18 Jan 2010

Obama announces $100M in aid for Haitian earthquake recovery

At the White House on Thursday, President Barack Obama "promised $100 million along with more American troops for the relief effort in Haiti, vowing that the United States would stand with the impoverished nation as it grappled with the devastation of its capital city," the New York Times reports.

18 Jan 2010

Study recommends improvements for scaling up child survival programs

New child survival programs must engage evaluation teams from the start to identify the major causes of child mortality in intervention areas and to ensure that appropriate resources are available to scale up coverage and treatment, according to a retrospective evaluation led by researchers at the Johns Hopkins Bloomberg School of Public Health.

13 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

UNICEF program aimed at curbing deaths in West Africa falls short of goals, study finds

A $27 million UNICEF program that aims to decrease disease-related child deaths in West Africa did not meet its goal of reducing death rates by at least 25 percent at the conclusion of 2006, according to a Lancet study published on Tuesday, the Associated Press reports.

13 Jan 2010

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary results from the first stage of a two-stage Phase 2 clinical study evaluating NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients enrolled with platinum-resistant disease were evaluable for the primary endpoint of overall response rate using Gynecologic Cancer InterGroup (GCIG) criteria, i.e., a combination of response by tumor imaging

12 Jan 2010

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

12 Jan 2010

Idenix Pharmaceuticals announces significant progress in HCV development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced significant progress in three HCV programs

12 Jan 2010

Cubist Pharmaceuticals reports total revenues for fourth-quarter and full-year 2009

Cubist Pharmaceuticals, Inc. today announced total revenues for both the fourth quarter and full year ended December 31, 2009.

11 Jan 2010

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

Recent releases in Global Health

A Lancet Comment examines the "grossly insufficient" progress towards meeting the Millennium Development Goal (MDG) of reducing under-5 child mortality. "Accelerated progress can be achieved, even in the poorest environments, through: integrated, evidence-driven, and community-based programmes that focus on addressing the major causes of death, including pneumonia, diarrhoea, newborn disorders, malaria, HIV, and undernutrition; reaching the unreached with a basic package of interventions at large scale and achieving coverage with equity; and using data for action and advocacy," the comment concludes (You et al., 1/9).

9 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Diarrhea News and Research

Latest Diarrhea News and Research

Ampyra receives FDA approval for improving walking in MS patients

New research suggests prolong breastfeeding is critical for reducing risk of gastroenteritis in infants

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Urgent aid shipment containing tents and family survival kits docked at Jacmel, Haiti

Humanitarian group's response targets vulnerable women and children in Haiti

Over-the-counter medications can help manage minor ailments

FDA extends Tarceva's sNDA review period

Obama announces $100M in aid for Haitian earthquake recovery

Study recommends improvements for scaling up child survival programs

First sulfite-free rectal suspension for UC

UNICEF program aimed at curbing deaths in West Africa falls short of goals, study finds

Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Idenix Pharmaceuticals announces significant progress in HCV development programs

Cubist Pharmaceuticals reports total revenues for fourth-quarter and full-year 2009

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

Recent releases in Global Health

3Sbio submits registrational clinical trial application for Feraheme injection

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in